Molecular characterisation of a panel of human ovarian carcinoma xenografts

European Journal of Cancer

Volumn 34, Issue 9, 1998, Pages 1432-1438

  Codegoni, A M ^a   Nicoletti, M I ^b   Buraggi, G ^a   Valoti, G ^b   Giavazzi, R ^b   D'Incalci, M ^a   Landoni, F ^c   Maneo, A ^c   Broggini, M ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b MARIO NEGRI INST PHARMACOL RES   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Cell cycle proteins; DNA repair; Drug resistance; Ovarian cancer; Xenografts

Indexed keywords

ANIMAL EXPERIMENT; ARTICLE; CELL CYCLE; DNA REPAIR; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; NUDE MOUSE; ONCOGENE NEU; OVARY CARCINOMA; PRIORITY JOURNAL; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BODY WEIGHT; CISPLATIN; CYCLIN-DEPENDENT KINASES; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; FEMALE; GENES, CDC; GENES, ERBB-2; GENES, MDR; GENES, P53; HUMANS; MICE; MUTATION; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS;

EID: 0032145522     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00075-6     Document Type: Article

References (35)

1. 1. Kristensen GB, Tropè C. Epithelial ovarian cancer. The Lancet 1997, 349, 113-117.
2. 2. van der Zee AG, Hollema H, de Brujin HWA, et al. Cell biological marker of drug resistance in ovarian carcinoma. Gynecol Oncol 1995, 58, 165-178.
3. 3. Hainaut P. The tumour suppressor protein p53: a receptor to genotoxic stress that controls cell growth and survival. Curr Opin Oncol 1995, 17, 76-82.
4. 4. Liebermann DA, Hoffman B, Steinman RA. Molecular controls of growth arrest and apoptosis: p53-dependent and independent pathways. Oncogene 1995, 11, 199-210.
5. 5. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994, 54, 4855-4878.
6. 6. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991, 253, 49-53.
7. 7. Hunter T, Pines J. Cyclins and cancer II: Cyclin D and CDK inhibitors come of age. Cell 1994, 79, 573-582.
8. 8. Morgan DO. Principles of CDK regulation. Nature 1995, 374, 131-134.
9. 9. Sherr CJ. Cancer cell cycles. Science 1996, 274, 1672-1677.
10. 10. Hirama T, Koeffler HP. Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood 1995, 86, 841-854.
11. 11. Massazza G, Tomasoni A, Lucchini V, et al. Intraperitoneal and subcutaneous xenografts of human ovarian carcinoma in nude mice and their potential in experimental therapy. Int J Cancer 1989, 44, 494-500.
12. 12. Nicoletti MI, Lucchini V, Massazza G, Abbott BJ, D'Incalci M, Giavazzi R. Antitumor activity of taxol (NSC-125973) in human ovarian carcinomas growing in the peritoneal cavity of nude mice. Ann Oncol 1993, 4, 151-155.
13. 13. Balconi G, Beccaglia P, Erba E, et al. Establishment and characterization of two new human ovarian cancer cell lines obtained from solid tumor and ascitic fluid of the same patient. Br J Cancer (in press).
14. 14. Massazza G, Lucchini V, Tomasoni A, et al. Malignant behavior and resistance to cisplatin of human ovarian carcinoma xenografts established from the same patient at different stages of the disease. Cancer Res 1991, 51, 6358-6362.
15. 15. Chirgwin JM, Przybyla AE, MacDonald RJ, Rutter WJ. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 1979, 18, 5294-5299.
16. 16. Cole SPC, Bhardwaj G, Gerlach JH, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992, 258, 1650-1654.
17. 17. El-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of P53 tumor suppression. Cell 1993, 75, 817-825.
18. 18. Papathanasiou MA, Kerr NCK, Robbins JH, et al. Induction by ionizing radiation of the gadd45 gene in cultured human cells: lack of mediation by protein kinase C. Mol Cell Biol 1991, 11, 1009-1016.
19. 19. Gross P, Nenah YB, Croop JM, Housman DE. Isolation and expression of a complementary DNA that confers multidrug resistance. Nature 1986, 323, 728-731.
20. 20. Coussens L, Yang-Feng TL, Liao YC, et al. Tynsine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985, 230, 1132-1139.
21. 21. Kaye SB. Ovarian cancer, from the laboratory to the clinic: challenges for the future. Ann Oncol 1996, 7, 9-13.
22. 22. Arao S, Suwa H, Mandai M, et al. Expression of multidrug resistance gene and localization of P-glycoprotein in human primary ovarian cancer. Cancer Res 1994, 54, 1355-1359.
23. 23. Imyanitov EN, Chernitsa OI, Serova OM, Knyazev PG. Rare occurrence of amplification of HER-2 (erbB-2/neu) oncogene in ovarian cancer patients [letter]. Eur J Cancer 1992, 28A, 1300.
24. 24. Shelling AN, Cooke IE, Ganesan TS. The genetic analysis of ovarian cancer. Br Cancer 1995, 72, 521-527.
25. 25. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994, 266, 1821-1828.
26. 26. Keyomarsi K, O'Leary N, Molnar G, Lees E, Fingert HJ, Pardee AB. Cyclin E, a potential prognostic marker for breast cancer. Cancer Res 1994, 54, 380-385.
27. 27. Dou Q-P, Pardee AB, Keyomarsi K. Cyclin E - a better prognostic marker for breast cancer than cyclin D? Nature Med 1996, 2, 254.
28. 28. Worsley SD, Ponder BAJ, Davies BR. Overexpression of cyclin Dl in epithelial ovarian cancers. Gynecol Oncol 1997, 64, 189-195.
29. 29. Porter PL, Malone KE, Heagerty PJ, et al. Expression of cellcycle regulators p27kip1 and cyclin E, alone or in combination, correlate with survival in young breast cancer patients. Nature Med 1997, 3, 222-225.
30. 30. Loda M, Cukor B, Tam SW, et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nature Med 1997, 3, 231-234.
31. 31. Catzavelos C, Bhattacharya N, Ung YC, et al. Decreased levels of the cell-cycle inhibitor p27kip1 protein: prognostic implications in primary breast cancer. Nature Med 1997, 3, 227-230.
32. 32. Lin J, Reichner C, Wu X, Levine AJ. Analysis of wild-type and mutant p21WAF-1 gene activities. Mol Cell Biol 1996, 16, 1786-1793.
33. 33. Nicoletti MI, Lucchini V, D'Incalci M, Giavazzi R. Comparison of paclitaxel and docetaxel activity on human ovarian carcinoma xenografts. Eur J Cancer 1994, 30, 691-696.
34. 34. Fajac A. DaSilva J, Ahomadegbe JC, et al. Cisplatin-induced apoptosis and p53 gene status in a cisplatin-resistant human ovarian carcinoma cell line. Int J Cancer 1996, 68, 67-74.
35. 35. Artuso M, Esteve A, Bresil H, Vuillaume M, Hall J. The role of the Ataxia telangiectasia gene in the p53, WAF1/CIP1(p21)-and GADD45-mediated response to DNA damage produced by ionising radiation. Oncogene 1995, 11, 1427-1435.